02 education & research
UNIVERSITY OF LUCERNE
PhD in Health Economics & Health Policy
Effectiveness of pricing policies for new, innovative health technologies in OECD countries. > publications
SWISS SCHOOL OF PUBLIC HEALTH
PhD Program: International Doctoral Courses in Health Economics & Policy
UNIVERSITY OF ST. GALLEN
Master in International Affairs & Governance
Economics, Political Sciences and Law.
UNIVERSITY OF ST. GALLEN
Bachelor in Business Administration
Additional courses of Bachelor in International Affairs for change of Major on Master level.
Head Analytics & National Contracts
Member of Executive Committee.
The HSK Purchasing Cooperative negotiates service contracts (tariffs) with Swiss health care providers on behalf of the three health insurance companies Helsana, Sanitas and KPT, representing approximately 25% of the Swiss mandatory health insurance market.
Head Market Access & Government Affairs
Member of Swiss Executive Committee. Responsible for patient access, evidence generation and public affairs activities. Relations with health authorities, trade associations, health insurances, university hospitals. Therapeutic areas: Oncology, Gastroenterology and Primary Care.
Market Access Manager
Preparation, submission and negotiation of reimbursement & pricing dossiers to / with the national health authority (BAG). Negotiation of individual patient cases with health insurances. Therapeutic areas: Immunology, Neurology, Virology, Oncology and Nephrology.
SWISS RE (SWISS REINSURANCE COMPANY)
Economic Reporting Analyst
Group Planning & Analysis. Analysis and valuation of assets and liabilities based on best estimates of underlying cash flows. Preparation of Swiss Re's EVM disclosure which is basis for regulatory reporting in Switzerland (FINMA) and the rest of the world.
HIRSLANDEN PRIVATE HOSPITAL GROUP
Executive Assistant, CEO team
Reporting for Board of Directors, Executive Committee and Clinic Directors. Presentations and briefings for CEO, Corporate Secretary, Head Public Affairs. Support in strategy, corporate / business development, acquisitions, public policy, etc.
Subjects: Business Administration, Economics & Law.
DEPARTMENT OF JUSTICE & HOME AFFAIRS, CANTON ZH
Research Assistant to Head of Office
Legislative project to reform the Cantonal Act on Fiscal Equalisation. Economic modelling for the new regulation, preparation of governmental communiques / decrees, responses to formal requests from the Cantonal parliament.
HEALTH ECONOMIST (PHD)
A future-proof Swiss healthcare system needs more evidence and transparency on outcomes and costs, more cross-sectoral, cross-regional collaboration across the entire treatment cycle, as well as “learning reimbursement systems”.
A future-proof Swiss healthcare system needs more data, evidence and transparency regarding medical outcomes and the associated costs. Only by establishing an informed discussion on added value (ratio of additional patient outcome to additional costs) and corresponding reimbursement systems will we promote the “right innovations” which we can also afford in the long term. For the benefit of patients and society.
All partners in the health care system (manufacturers, service providers, insurers and authorities) must commit to the improved availability of data, evidence and transparency. However, not only evidence and transparency are needed, but also consequence: therapy offers must be committed to their added value (“value-based pricing”). Evidence-based minimum case numbers per therapy area must be defined and enforced for service providers. New therapies must be regularly reviewed for their effectiveness and cost-effectiveness.
There is also a need for improved cooperation between all actors in all areas of care planning and service provision. For Switzerland, this requires in particular supra-regional care planning: our fragmented hospital landscape urgently needs more consolidation.
Above all, however, a sustainably financeable Swiss health system can only be guaranteed if we establish “learning reimbursement systems” in all service and tariff areas that are able to reflect progress in medicine, technology and the organisation of service provision.